We're developing mitochondrial protective small molecules for epilepsy, Parkinson's and mitochondrial diseases. Our lead clinical candidate NT102 is for Dravet syndrome, a rare epilepsy affecting ~35,000 people in the US and EU. NT102 has striking efficacy as a monotherapy in many animal seizure models, and works as an adjunct with additive antiseizure activity with no adverse drug-drug effects so far. NT102 is well-tolerated, non-sedating, brain-penetrating, fast-acting and targets a new mechanism of action (mitochondrial protection) that is differentiated and complementary to current antiseizure medications. We've received FDA Orphan Drug Designation for NT102 and label expansion for broader pharmacoresistant epilepsies (which is a third of all epilepsies, and the newer generation drugs have generated $3B in this space) will be pursued after approval for Dravet. We seek $10M for IND-enabling studies and Phase I trials in Australia, and pharma partnership to develop NT102. We recently won the 2022 BioHealth Capital Region "Crab Trap" pitch competition.